PATIENT-REPORTED OUTCOMES IN THOSE CONSUMING MEDICAL CANNABIS: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY IN CHRONIC PAIN PATIENTS

In this observational study conducted by Dr. Hance Clarke et al, around 1000 patients with Chronic diseases from multiple Cannabis Clinics in Toronto, Canada were enrolled between Sept 2015 and Jul 2018. Patients completed questionnaires at different times of their medical visits, by which their demographics, patterns of cannabis use and the long-term effectiveness of cannabis on their pain, anxiety, depression, quality of life, general health symptoms, self-reported opioid consumption, and adverse events were assessed. 217 (28%) completed the six-month questionnaire and reported continuing the consumption of cannabis. Pain scores were significantly reduced, and quality of life was improved.

Although 28% represents only about a third of the patients included in the study, these results contribute to the current evidence on cannabinoid-based medicine and highlight the need to continue conducting well-designed controlled studies not only on the therapeutic effect of cannabis but also on the type and quality of accessible cannabinoid products in real life.

  Read More >>>

MEDICAL CANNABIS 2.0 – ADVANCEMENTS IN CANNABINOID RESEARCH, PRODUCT OFFERINGS AND PATIENT ACCESS
The 3rd annual Avicanna Symposium, “Medical Cannabis 2.0 – The Advancements in Cannabinoid Research, Product Offerings, and Patient Access”, was held virtually due to COVID-19 restrictions on the 21st of July, 2020. The purpose of the Symposium was to highlight the current state of advancements in the medical cannabis industry in Canada and abroad as well as underlining the key areas of research and product development. In addition, the speakers address patient access for medical cannabis products currently being offered on the market. This event brought together more than 1,000 participants including clinicians, researchers, regulatory affairs specialists, investors, members of the pharmaceutical industry and key representatives in the Canadian cannabis field.

Watch Full Video >>> |     Read More >>>

THE EMERGENCE OF BIOPHARMACEUTICAL CANNABINOIDS FROM RESEARCH & DEVELOPMENT TO CLINICAL TRANSLATION
The 2nd annual Avicanna Symposium, “The Emergence of Biopharmaceutical Cannabinoids – From Research & Development to Clinical Translation”, was held at the MaRS Discovery District (Canada’s premium launchpad for start-ups), Toronto, Canada on 25th March 2019. The Symposium was the first to be held in Canada by Avicanna, with the inaugural Symposium taking place in Santa Marta, Colombia, May 2018.

  Read More >>>

This is the first edition of our newsletter series, which will provide a range of bio-pharmaceutical topics and updates in the emerging field of cannabinoid research and clinical development. The objective of this newsletter is to create awareness of the latest and most significant cannabinoid-based research that is conducted worldwide, and available to the research community. Furthermore, we hope this newsletter serves to engage the medical and scientific community to continue building and fostering strong academic and clinical relationships.

  Read More >>>

In this edition of our newsletter series, we focus on a recent publication that reviews the medical evidence for the treatment of chronic non-cancer pain (CNCP) with medical cannabis. This publication emphasizes the importance of interpreting the evidence of cannabis-based treatments towards specific CNCP, which aligns with Avicanna’s scientific and evidence-based approach for developing its cannabinoid-based products.

  Read More >>>

This newsletter explores cannabinoid applications in the treatment of epilepsy. Currently, there is significant evidence supporting medical cannabis as an adjunctive solution in epilepsy aside other treatments, however, there remains a paucity for research that proves cannabinoid-based therapies to be both independent and sustainable solutions to this disorder.

  Read More >>>